Skip to main content
Fig. 6 | Experimental Hematology & Oncology

Fig. 6

From: Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells

Fig. 6

Chidamide plus apatinib impact the glucose metabolism independent of the mitochondrial activity and perturb the VEGFR signaling. A, B Examination of the mitochondrial respiration and glycolytic function in CD34+CD38− KG1α cells treated with chidamide and apatinib alone or in combination. C Western blotting analysis of the expression levels of the indicated proteins in CD34+CD38− KG1α and primary AML cells exposed to designated doses of apatinib and chidamide alone or in combination. Apa and Chi represent apatinib and chidamide, respectively. D Immunohistochemistry analysis of the exprssion levels of VEGFR, BCL2 and MCL1 in both spleen (left panel) and bone marrow (right panel) in AML PDX mice administered with vehicle, chidamide, apatinib, or the combined treatment groups. E, F Quantification of the protein levels of VEGFR, BCL2 and MCL1 in spleen (E) and bone marrow (F) in AML PDX mice administered with distinct treatment groups. Apa, Chi and Combo represent apatinib, chidamide and the combination of the two drugs, respectively. *, ** and *** indicates p < 0.05, p < 0.01, p < 0.001, respectively. ns indicates not significant

Back to article page